Five AGORA members—Prof. Fernanda Herrera, Dr. Krisztian Homicsko, Prof. Andreas Hottinger, Prof. Etienne Meylan, and Prof. Jean Yannis Perentes—have been awarded grants as co-applicants or principal applicants in cutting-edge oncology research projects funded by the Swiss Cancer Research Foundation:
Prof. Fernanda Herrera (UNIL & CHUV Oncology) is co-applicant, alongside Prof. Sana Intidhar Labidi-Galy, on a clinical study combining induction chemotherapy and pembrolizumab followed by chemo-radiation for locally advanced cervical cancer.
Dr. Krisztian Homicsko (CHUV Oncology) is co-applicant, together with Prof. Marianna Rapsomaniki, Prof. Maria Brbić, and Prof. Sabina Berezowska, on a project using AI and spatial transcriptomics to develop precision oncology tools for mesothelioma.
Prof. Andreas Hottinger (UNIL & CHUV Neurosciences & Oncology) is co-applicant, with Dr. Christophe Galland and Dr. Sabine Galland, on a project developing a non-invasive blood-based monitoring method for glioblastoma using SERS optical spectroscopy.
Prof. Etienne Meylan (CHUV Thoracic Surgery) is principal applicant, together with co-applicants Prof. Jean Yannis Perentes (CHUV Thoracic Surgery) and Prof. Solange Peters (CHUV Oncology), on a project aiming to functionally characterise a new metabolic subset of tumor-associated neutrophils in the development of non-small cell lung cancer.
This year, the Swiss Cancer Research Foundation selected 32 projects out of 129 submissions, awarding CHF 10.7 million to support innovative cancer research across Switzerland. The Foundation prioritizes scientific excellence and clinical relevance through a highly competitive selection process.
For more information:
